Products & Tech | Page 52 of 63

Santarus to Launch Novel Type 2 Diabetes Drug CYCLOSET

San Diego based Santarus, a biopharmaceutical company, announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a FDA approved prescription drug to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents...

Biodel Scientists Report on “Smart Insulin” at 10th Annual Diabetes Technology Meeting

Scientists from Biodel Inc. reported new findings from the company's Linjeta™, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD...

Voxiva Inc. and PositiveID Partner to Offer an Integrated Mobile Diabetes Solution

Voxiva Inc. and PositiveID Corporation, announced that they are integrating PositiveID's wireless iglucose system with Voxiva's care4life diabetes management program. This will create an innovative, end-to-end wireless diabetes management solution, which the companies will showcase together at the mHealth Summit in Washington, DC on November 8-10...

KOMBIGLYZE XR Approved for the Treatment of Type 2 Diabetes

Bristol-Myers Squibb Company and AstraZeneca announced FDA approval of KOMBIGLYZE™ XR, the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR offers...

FDA Issues Complete Response Letter to Biodel New Diabetes Drug Application

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) requesting additional information regarding Biodel Inc.'s new drug application (NDA) for Linjeta a more-rapid-acting human insulin injection for the treatment of type 1 and type 2 diabetes. The CRL stated that the FDA's review cycle is complete and that the application cannot be...

FDA Requests Further Testing On Amylin’s New Type 2 Diabetes Drug

In the complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide extended-release for injectable suspension) issued Tuesday the FDA requested Amylin Pharmaceuticals, Eli Lilly and Alkermesa conduct a thorough QT study which would look at the new drug's effect on patients' heart rates...

FDA Requests Further Testing On Amylin’s New Type 2 Diabetes Drug

In the complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide extended-release for injectable suspension) issued Tuesday the FDA requested Amylin Pharmaceuticals, Eli Lilly and Alkermesa conduct a thorough QT study which would look at the new drug's effect on patients' heart rates...

Is Insulin Enough? Developing C-Peptide Therapy

Cebix Incorporated, based in San Diego, California, has started looking at another missing component of beta cell secretion: C-peptides.

D. Medical Insulin Pump to be Distributed in Greece

D. Medical Industries Ltd. announced the execution of a distribution agreement with Pharmaserve-Lilly S.A.C.I. ("Pharmaserve-Lilly") for the distribution of its ADI durable insulin pump, related consumables and its Universal Detach Detect Infusion Sets in Greece. The ADI pump, developed by D. Medical subsidiary Spring, is the only insulin pump on the market today that implements a spring-based...

Insulin Pump Smackdown: Revel vs 522

I’ve been wearing the newest pump available from Minimed in the U.S., the Revel, for almost four months now. Minimed made it available to me through their temporary loaner pump program, and have kindly allowed me to hang on to it while I decide whether the Revel, an upgrade from the Minimed 522 I currently own, is worth the $400 that it costs to upgrade via their Paradigm Pathway Program.